📰 Drug Controller General News
Drug Controller General News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Drug Controller General. Real-time updates on events, politics, business and more.
May 31, 2024
The Drug Controller General of India (DCGI) has asked drug regulators in all states and Union territories to withdraw AstraZenecas anti-cancer drug Olaparib tablets for treatment in patients who have received three or more prior lines of chemotherapy.
May 29, 2024
Wockhardt Limited reports reduced net loss, plans to launch new antibiotics, files patents, and raises funds for growth.
May 24, 2024
DCGI orders withdrawal of AstraZeneca's Olaparib tablets for gBRCA mutation and advanced ovarian cancer due to potential adverse effects. The drug was
May 23, 2024
The communication stated that the firm presented the clinical evidence for the withdrawal of indication of Olaparib tablets.
May 23, 2024
Oncologists on Thursday supported the Drug Controller General of India's (DCGI) mandate to state authorities to withdraw AstraZeneca's anticancer generic drug Olaparib over safety concerns.Olaparib is a chemotherapy drug and is used to treat ...
May 23, 2024
Cgi orders withdrawal of cancer drug olaparib for certain treatments
May 22, 2024
Get latest articles and stories on India at LatestLY. The Drug Controller General of India has asked drug regulators in all states and Union territories to withdraw AstraZeneca's anti-cancer drug Olaparib tablets for treatment in patients who have received three or more prior lines of chemotherapy. India News | DCGI Orders Withdrawal of Cancer Drug Olaparib for Certain Treatments.
May 22, 2024
Indias DCGI orders the withdrawal of Olaparib for specific cancer treatments after reviewing adverse effects and survival data.
May 3, 2024
DIMAPUR, MAY 3 (MExN): The All India Organization of Chemists and Druggists (AIOCD) has expressed deep concern over the Central government’s proposal to permit the sale of Over-The-Counter (OTC) drugs without a license in India.
April 29, 2024
India enforced Schedule M for drug manufacturers, emphasizing quality, recall systems. Companies must comply with strict rules on hygiene, audits, and reporting defects to DCGI for improved drug quality and safety measures. For seamless implementation of the new rules, the health ministry has been conducting workshops and giving presentations to pharma companies.